HelloBetter

HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.